Endocrine aspects of acute and prolonged critical illness

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 1, 2006, Pages 20-31

  Vanhorebeek, Ilse ^a   Langouche, Lies ^a   Van Den Berghe, Greet Den ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Critical illness; Endocrine changes; Therapeutic implications

Indexed keywords

CATECHOLAMINE; GONADORELIN; GROWTH HORMONE; HYDROCORTISONE; HYPOTHALAMUS RELEASING FACTOR; PROLACTIN; THYROID HORMONE; VASOPRESSIN;

ADRENAL GLAND; CRITICAL ILLNESS; DISEASE SEVERITY; ENDOCRINE DISEASE; HORMONE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSULIN RESISTANCE; INSULIN TREATMENT; METABOLIC DISORDER; PRIORITY JOURNAL; REVIEW; SURVIVAL;

ACUTE DISEASE; ADRENAL GLANDS; CATECHOLAMINES; CHRONIC DISEASE; CRITICAL ILLNESS; ENDOCRINE SYSTEM; GONADS; HORMONES; MODELS, BIOLOGICAL; THYROID GLAND; VASOPRESSINS;

EID: 33646534368     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0071     Document Type: Review

References (80)

1. Takala J et al. (1999) Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341: 785-792
2. CRASH trial collaborators (2004) Effect of intravenous corticosteroids on death within 14 days in 10,008 adults with clinically significant head injury (MRC CRASH trial): a randomized placebo-controlled trial. Lancet 364: 1321-1328
3. Debaveye YA and Van den Berghe GH (2004) Is there still a place for dopamine in the modern intensive care unit? Anesth Analg 98: 461-468
4. Van den Berghe G et al. (1998) Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 83: 1827-1834
5. Weekers F et al. (2002) A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response. Endocrinology 143: 764-774
6. Bowers CY et al. (1984) On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114: 1537-1545
7. Howard AD et al. (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 27: 974-977
8. Kojima M et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660
9. Van den Berghe G et al. (2000) A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 85: 183-192
10. Ross R et al. (1991) Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol (Oxf) 35: 47-54
11. Baxter RC et al. (1998) Thirty day monitoring of insulin-like growth factor and their binding proteins in intensive care unit patients. Growth Horm IGF Res 8: 455-463
12. Hermansson M et al. (1997) Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: demonstration of reduced expression after elective surgery. J Clin Endocrinol Metab 82: 421-428
13. Defalque D et al. (1999) GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. Am J Physiol Endocrinol Metab 276: 565-572
14. Van den Berghe G et al. (1997) The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 82: 590-599
15. Van den Berghe G et al. (1998) Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 83: 309-319
16. Van den Berghe G et al. (1999) Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 84: 1311-1323
17. Yen PM (2001) Physiological and molecular basis of thyroid hormone action. Physiol Rev 81: 1097-1142
18. Bianco AC et al. (2002) Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23: 38-89
19. Friesema ECH et al. (2005) Thyroid hormone transporters. Biochem Soc Trans 33: 228-232
20. 3 concentration and serum IL-6 rise and TNFα in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab 86: 4198-4205
21. Van den Berghe G (2000) Novel insights into the endocrinology of critical illness. Eur J Endocrinol 143: 1-13
22. Romijn JA and Wiersinga WM (1990) Decreased nocturnal surge of thyrotropin in nonthyroidal illness. J Clin Endocrinol Metab 70: 35-42
23. van der Poll T et al. (1995) Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab 80: 1341-1346
24. Lim CF et al. (1993) Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and nonesterified fatty acids. J Clin Endocrinol Metab 76: 1165-1172
25. Gardner DF et al. (1979) Effect of triiodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med 300: 579-584
26. De Groot LJ (1999) Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 84: 151-164
27. Van den Berghe G et al. (1997) Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf) 47: 599-612
28. Fliers E et al. (1997) Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with non-thyroidal illness. J Clin Endocrinol Metab 82: 4032-4036
29. Van den Berghe G et al. (1994) Dopamine and the euthyroid sick syndrome in critical illness. Clin Endocrinol (Oxf) 41: 731-737
30. Faglia G et al. (1973) Reduced plasma thyrotropin response to thyrotropin releasing hormone after dexamethasone adminstration in normal subjects. Horm Metab Res 5: 289-292
31. Peeters RP et al. (2003) Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 88: 3202-3211
32. 3 are prognostic markers in critically ill patients and are associated with post-mortem tissue deiodinase activities. J Clin Endocrinol Metab 90: 4559-4565
33. Weekers F et al. (2004) Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. Endocrinology 145: 205-213
34. Debaveye Y et al. (2005) Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin releasing hormone and its combination with growth hormone releasing peptide-2. Endocrinology 146: 5604-5611
35. Spratt DI (2001) Altered steroidogenesis in critical illness: is treatment with anabolic steroids indicated? Best Pract Res Clin Endocrinol Metab 15: 479-494
36. Wang C et al. (1978) Effect of surgical stress on pituitary-testicular function. Clin Endocrinol (Oxf) 9: 255-266
37. Wang C et al. (1978) Effect of acute myocardial infarction on pituitary-testicular function. Clin Endocrinol (Oxf) 9: 249-253
38. Dong Q et al. (1992) Circulating immunoreactive inhibin and testosterone levels in men with critical illness. Clin Endocrinol (Oxf) 36: 399-404
39. Rivier C and Vale W (1989) In the rat, interleukin-1 α acts at the level of the brain and the gonads to interfere with gonadotropin and sex steroid secretion. Endocrinology 124: 2105-2109
40. Guo H et al. (1990) Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis. Endocrinology 127: 1234-1239
41. Vogel AV et al. (1985) Pituitary-testicular axis dysfunction in burned men. J Clin Endocrinol Metab 60: 658-665
42. Woolf PD et al. (1985) Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 60: 444-450
43. Van den Berghe G et al. (1994) Luteinizing hormone secretion and hypoandrogenemia in critically ill men: effect of dopamine. Clin Endocrinol (Oxf) 41: 563-569
44. Van den Berghe G et al. (2001) Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. J Clin Endocrinol Metab 86: 3217-3226
45. Cicero TJ et al. (1975) Function of the male sex organs in heroin and methadone users. N Engl J Med 292: 882-887
46. Ben-Jonathan N (1985) Dopamine: a prolactin-inhibiting hormone. Endocr Rev 6: 564-589
47. Noel GL et al. (1972) Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab 35: 840-851
48. Meakins JL et al. (1977) Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg 186: 241-250
49. Devins SS et al. (1992) Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. Crit Care Med 20: 1644-1649
50. Cooper MS and Stewart PM (2003) Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348: 727-734
51. Rivier C and Vale W (1983) Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 305: 325-327
52. Marik PE and Zaloga GP (2002) Adrenal insufficiency in the critically ill. A new look at an old problem. Chest 122: 1784-1796
53. Pemberton PA et al. (1988) Hormone binding globulins undergo serpin conformational change in inflammation. Nature 336: 257-258
54. Hammond GL et al. (1990) A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab 71: 34-39
55. Beishuizen A et al. (2001) Patterns of corticosteroid-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 27: 1584-1591
56. Hamrahian AH et al. (2004) Measurements of serum free cortisol in critically ill patients. N Engl J Med 350: 1629-1638
57. Finlay WEI and McKee JI (1982) Serum cortisol levels in severely stressed patients. Lancet 1: 1414-1415
58. Rothwell PM et al. (1991) Cortisol response to corticotropin and survival in septic shock. Lancet 337: 582-583
59. Span LFR et al. (1992) Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 18: 93-96
60. Annane D et al. (2000) A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 283: 1038-1045
61. Annane D et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288: 862-871
62. Sam S et al. (2004) Cortisol levels and mortality in severe sepsis. Clin Endocrinol (Oxf) 60: 29-35
63. Bornstein SR and Chrousos GP (1999) Adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 84: 1729-1736
64. Vermes I and Beishuizen A (2001) The hypothalamic-pituitary-adrenal response to critical illness. Best Pract Res Clin Endocrinol Metab 15: 495-511
65. Barquist E and Kirton O (1997) Adrenal insufficiency in the surgical intensive care unit patient. J Trauma 42: 27-31
66. den Ouden DT and Meinders AE (2005) Vasopressin: physiology and clinical use in patients with vasodilatory shock: a review. Neth J Med 63: 4-13
67. Boldt J et al. (1996) Influence of different volume therapy regimens on regulators of the circulation in the critically ill. Br J Anaesth 77: 480-487
68. Viquerat CE et al. (1985) Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. Am J Med 78: 455-460
69. Russell-Jones DL et al. (1994) Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans. Am J Physiol Endocrinol Metab 267: 591-598
70. Minneci PC et al. (2004) Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 141: 47-56
71. Stathatos N et al. (2001) The controversy of the treatment of critically ill patients with thyroid hormone. Best Pract Res Clin Endocrinol Metab 15: 465-478
72. Ferrando AA et al. (2001) Testosterone administration in severe burns ameliorates muscle catabolism. Crit Care Med 29: 1936-1942
73. Angele MK et al. (1998) Testosterone: the culprit for producing splenocyte immune depression after trauma hemorrhage. Am J Physiol Cell Physiol 274: 1530-1536
74. Holmes CL (2005) Vasoactive drugs in the intensive care unit. Curr Opin Crit Care 11: 413-417
75. Van den Berghe G et al. (2002) The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 56: 655-669
76. Vanhorebeek I et al. (2005) Glycemic and nonglycemic effects of insulin: how do they contribute to a better outcome of critical illness? Curr Opin Crit Care 11: 304-311
77. Van den Berghe G et al. (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345: 1359-1367
78. Van den Berghe G et al. (2005) Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 64: 1348-1353
79. Van den Berghe G et al. (2003) Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 31: 359-366
80. Van den Berghe G (2004) How does blood glucose control with insulin save lives in intensive care? J Clin Invest 114: 1187-1195